Shares of Affimed NV (NASDAQ:AFMD) saw strong trading volume on Thursday . 2,774,334 shares changed hands during trading, an increase of 156% from the previous session’s volume of 1,081,733 shares.The stock last traded at $3.71 and had previously closed at $3.15.
A number of equities research analysts recently commented on the stock. ValuEngine lowered shares of Affimed from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. BMO Capital Markets upped their price target on shares of Affimed from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Tuesday, August 28th. Zacks Investment Research upgraded shares of Affimed from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Tuesday, October 9th. Jefferies Financial Group upgraded shares of Affimed from a “hold” rating to a “buy” rating and upped their price target for the company from $1.80 to $4.00 in a report on Tuesday, August 28th. Finally, BidaskClub lowered shares of Affimed from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Affimed currently has a consensus rating of “Buy” and a consensus target price of $4.81.
The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36.
Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.01. The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.61 million. Affimed had a negative net margin of 1,723.04% and a negative return on equity of 74.04%. As a group, research analysts forecast that Affimed NV will post -0.61 earnings per share for the current year.
Institutional investors have recently modified their holdings of the business. Stanley Laman Group Ltd. purchased a new position in Affimed during the 2nd quarter valued at $100,000. Barclays PLC increased its position in Affimed by 385.3% during the 1st quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 51,573 shares during the period. Canada Pension Plan Investment Board purchased a new position in Affimed during the 2nd quarter valued at $165,000. Renaissance Technologies LLC increased its position in Affimed by 38.8% during the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 49,610 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Affimed by 28.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares during the period. 40.60% of the stock is currently owned by institutional investors and hedge funds.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: What is the 52-week high/low?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.